NCT00770198

sgp130 in Chronic Human Liver Disease

Study of IL-6 Transsignaling in Chronic Human Liver Disease

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 129 (actual)
• Sponsor: Erasme University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Chronic liver disease are characterized by increased levels of plasma IL-6, but the bioactivity of this cytokine in this disease is not well known. IL-6 receptor complex is regulated by multiple receptors subunits: the soluble form of IL-6 Receptor enhance IL-6 signal by a process called trans-signaling on cells expressing few membrane IL-6 receptors. Soluble gp130 is the natural inhibitor of IL-6 trans-signaling. The aim of this study is to characterize circulating and liver levels of theses compounds of IL-6 receptor complex, to unravel the bioactivity of IL-6 in this disease.

Detailed description

Consecutive patients undergoing transjugular liver biopsies for alcoholic liver disease or hepatitis C virus infection will be included in the study to measure plasma cytokines levels, peripheral blood mononuclear cells cytokine release and liver IL-6R compounds mRNA levels.

Conditions

• Alcoholic Liver Disease
• Chronic Hepatitis C Virus Infection

Timeline

• Start date: 2005-01-01
• Primary completion: 2007-01-01
• Completion: 2008-10-01
• First posted: 2008-10-09
• Last updated: 2008-10-09

Locations

1 site across 1 country: Belgium